Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Revolution Medicines (RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Revolution Medicines (RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference. The company's CEO and chairman, Mark A. Goldsmith, M.D., Ph.D., will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 10:30 a.m. ET.
The presentation will be accessible via live webcast through the company's investor relations website under the 'Events & Presentations' section. Interested parties can view a replay of the webcast on the same platform for at least 14 days following the conference.
Details
News Market Reaction – RVMD
The recorded move for RVMD in the trading session of this news was +5.25%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 10:30 a.m. ET.
To access the live webcast of the presentation, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.